Company: INKT
Filing Date: 2025-07-14
Form Type: 8-K
Source: 0000950170-25-095460
Chunk: 0

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-14
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On July 11, 2005, MiNK Therapeutics, Inc. (“ MiNK” or the “ Company”), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, announced the publication of another landmark case in Nature’sOncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy. The publication, titled“ Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,” presents a patient case from MiNK’s clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy - including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti - PD-1, anti - CTLA-4, and anti - TIGIT) - and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).

In addition, at the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Extended survival beyond 12 months was observed in several patients. In a separate peer-reviewed case report published inOncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab.

The ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional readouts expected in upcoming months.

Forward-Looking Statements

This current report contains “forward-looking statements” within the meaning of the U. S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,”